Company:  ANNEXON, INC. (ANNX)
Form Type:  4
Filing Date:  7/30/2020 
CIK:  0001528115 
Address:  180 KIMBALL WAY
SUITE 200
 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650)-822-5500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$22.50  
Change: 
1.21 (5.68%)  
Trade Time: 
Sep 18  
Market Cap: 
$858.33M
Trade ANNX now with 

© 2020  
Description of Business
We are a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Our pipeline is based on our platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Evidence suggests that potent and selective inhibition of C1q can prevent tissue damage triggered in antibody-mediated autoimmune disease and preserve loss of functioning synapses associated with cognitive and functional decline in complement-mediated neurodegeneration.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES